Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes
- PMID: 36704045
- PMCID: PMC9871554
- DOI: 10.3389/fendo.2022.1090842
Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes
Abstract
Background: Considered a significant risk to health and survival, type 1 diabetes (T1D) is a heterogeneous autoimmune disease characterized by hyperglycemia caused by an absolute deficiency of insulin, which is mainly due to the immune-mediated destruction of pancreatic beta cells.
Scope of review: In recent years, the role of immune checkpoints in the treatment of cancer has been increasingly recognized, but unfortunately, little attention has been paid to the significant role they play both in the development of secondary diabetes with immune checkpoint inhibitors and the treatment of T1D, such as cytotoxic T-lymphocyte antigen 4(CTLA-4), programmed cell death protein-1(PD-1), lymphocyte activation gene-3(LAG-3), programmed death ligand-1(PD-L1), and T-cell immunoglobulin mucin protein-3(TIM-3). Here, this review summarizes recent research on the role and mechanisms of diverse immune checkpoint molecules in mediating the development of T1D and their potential and theoretical basis for the prevention and treatment of diabetes.
Major conclusions: Immune checkpoint inhibitors related diabetes, similar to T1D, are severe endocrine toxicity induced with immune checkpoint inhibitors. Interestingly, numerous treatment measures show excellent efficacy for T1D via regulating diverse immune checkpoint molecules, including co-inhibitory and co-stimulatory molecules. Thus, targeting immune checkpoint molecules may exhibit potential for T1D treatment and improve clinical outcomes.
Keywords: immune checkpoint inhibitors; immune checkpoints; immunotherapy; lymphocyte; type 1 diabetes.
Copyright © 2023 Ding, Yang, Lin, Cao and Zou.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Immune checkpoints and cancer development: Therapeutic implications and future directions.Pathol Res Pract. 2021 Jul;223:153485. doi: 10.1016/j.prp.2021.153485. Epub 2021 May 15. Pathol Res Pract. 2021. PMID: 34022684 Review.
-
Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.ESMO Open. 2024 Apr;9(4):102942. doi: 10.1016/j.esmoop.2024.102942. Epub 2024 Mar 18. ESMO Open. 2024. PMID: 38503143 Free PMC article.
-
Anticancer natural products targeting immune checkpoint protein network.Semin Cancer Biol. 2022 Nov;86(Pt 3):1008-1032. doi: 10.1016/j.semcancer.2021.11.006. Epub 2021 Nov 25. Semin Cancer Biol. 2022. PMID: 34838956 Review.
-
Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.Curr Med Chem. 2020;27(15):2402-2448. doi: 10.2174/0929867325666181106114421. Curr Med Chem. 2020. PMID: 30398102 Review.
-
Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer-Narrative Review.Int J Mol Sci. 2024 Jun 12;25(12):6471. doi: 10.3390/ijms25126471. Int J Mol Sci. 2024. PMID: 38928174 Free PMC article. Review.
Cited by
-
Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection.Front Endocrinol (Lausanne). 2024 May 10;15:1377322. doi: 10.3389/fendo.2024.1377322. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38800484 Free PMC article. Review.
-
The Relationship between Type 1 Diabetes Mellitus, TNF-α, and IL-10 Gene Expression.Biomedicines. 2023 Apr 7;11(4):1120. doi: 10.3390/biomedicines11041120. Biomedicines. 2023. PMID: 37189738 Free PMC article.
-
Physiological and pathogenic T cell autoreactivity converge in type 1 diabetes.Nat Commun. 2024 Oct 29;15(1):9204. doi: 10.1038/s41467-024-53255-9. Nat Commun. 2024. PMID: 39472557 Free PMC article.
-
Brain-immune interactions: implication for cognitive impairments in Alzheimer's disease and autoimmune disorders.J Leukoc Biol. 2024 Nov 27;116(6):1269-1290. doi: 10.1093/jleuko/qiae134. J Leukoc Biol. 2024. PMID: 38869088 Free PMC article. Review.
-
Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease.Nat Commun. 2024 Jul 9;15(1):5748. doi: 10.1038/s41467-024-50007-7. Nat Commun. 2024. PMID: 38982041 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials